Sugi Predict

Sugi Predict / Compounds / SCHEMBL7185568

SCHEMBL7185568

SCHEMBL7185568

Cc1cccc(Cl)c1C(=O)Pc1ccc(Oc2ccccc2)cc1.[LiH]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FABP3 P05413 1/20 0.40
▸ FABP4 P15090 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ DAGLA Q9Y4D2 1/20 0.39
▸ TRPM4 Q8TD43 1/20 0.39
▸ PGR P06401 2/20 0.39
▸ PTGS1 P23219 1/20 0.37
▸ LTA4H P09960 1/20 0.37
▸ NR1H2 P55055 1/20 0.37
▸ BAX Q07812 1/20 0.37
▸ MAPT P10636 2/20 0.36
▸ PTK2B Q14289 1/20 0.36
▸ TYK2 P29597 1/20 0.36
▸ SRD5A2 P31213 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ FFAR1 O14842 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7183570 0.92 DAGLA (0.43) MEN1KMT2ADAGLAPGRLTA4H
SCHEMBL7180835 0.90 MEN1 (0.43) MEN1CYP2D6KMT2APTGS1LTA4H
SCHEMBL7175177 0.87 FABP3 (0.46) FABP3FABP4KMT2ATRPM4MAPT
SCHEMBL7182030 0.86 KMT2A (0.41) KMT2AMAPTTYK2LMNATDP1
SCHEMBL7190107 0.86 CA12 (0.43) FABP4MEN1KMT2ADAGLAPGR
SCHEMBL7184881 0.85 MEN1 (0.41) FABP3FABP4MEN1CYP2D6KMT2A
SCHEMBL7187697 0.85 FABP3 (0.48) FABP3FABP4MEN1KMT2ATRPM4
SCHEMBL7179694 0.84 FFAR1 (0.45) PTGS1LMNAL3MBTL1FFAR1
SCHEMBL7175322 0.83 TYK2 (0.41) FABP3FABP4KMT2ATRPM4MAPT
SCHEMBL7175036 0.83 KMT2A (0.40) FABP3FABP4MEN1CYP2D6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 FABP3 3252/4885FABP4 4550/4885MEN1 2312/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 FABP3 2807/4885FABP4 4256/4885MEN1 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.